Skip to main content

Table 3 Compliance and persistence measures of users experienced to disease-modifying agents

From: Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study

  Fingolimod Interferon beta-1b Intramuscular interferon beta-1a Subcutaneous interferon beta-1a Glatiramer acetate
  N=152 N=35 N=66 N=98 N=115
    p-value   p-value   p-value   p-value
PDC: mean (SD) 0.83 (0.23) 0.61 (0.30) 0.0002 0.67 (0.32) 0.0004 0.68 (0.31) 0.0001 0.73 (0.30) 0.0040
PDC Categories (%)          
 0-<0.2 4.61 17.14 0.0009 9.09 0.0002 10.20 0.0002 6.09 0.0003
 0.2-<0.4 3.95 8.57   22.73   11.22   11.30  
 0.4-<0.6 2.63 11.43   4.55   12.24   13.91  
 0.6-<0.8 15.13 22.86   10.61   18.37   7.83  
 0.8-1 73.68 40.00   53.03   47.96   60.87  
MPR: mean (SD) 0.92 (0.08) 0.82 (0.18) 0.0066 0.88 (0.13) 0.0287 0.84 (0.19) 0.0004 0.89 (0.16) 0.0602
MPR Categories (%)    0.0001   0.0069   0.0004   0.0106
 0-<0.2 0.00 0.00   0.00   1.10   0.93  
 0.2-<0.4 0.00 3.33   0.00   3.30   1.85  
 0.4-<0.6 0.00 10.00   5.00   5.49   5.56  
 0.6-<0.8 9.52 16.67   16.67   18.68   6.48  
 0.8-1 90.48 70.00   78.33   71.43   85.19  
Persistence (<60 day gap) (%) 74.34 42.86 0.0003 53.03 0.0020 54.08 0.0009 62.61 0.0396
Persistent days (days till first 60-day gap) (%)          
 No gap 74.34 42.86   53.03   54.08   62.61  
 1-90 6.58 22.86   15.15   19.39   12.17  
 91-180 4.61 5.71   21.21   10.20   13.91  
 181-270 9.21 17.14   6.06   10.20   6.96  
 270+ 5.26 11.43   4.55   6.12   4.35  
Switched to other DMTs after discontinuation (%) 4.61 11.43 0.1219 13.64 0.0188 9.18 0.1488 13.04 0.0130
  1. P-values based on comparison with fingolimod cohort, using Chi-square tests for categorical variables and Student’s t-tests for continuous variables.
  2. DMT: disease-modifying therapy. SD: standard deviation. PDC: proportion of days covered. MPR: medication procession ratio.